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Bacterial resistance to antibiotics in community-acquired respiratory tract infections is a
serious problem and is increasing in prevalence world-wide at an alarming rate.
Streptococcus pneumoniae, one of the main organisms implicated in respiratory tract
infections, has developed multiple resistance mechanisms to combat the effects of most
commonly used classes of antibiotics, particularly the b-lactams (penicillin, aminopeni-
cillins and cephalosporins) and macrolides. Furthermore, multidrug-resistant strains of
S. pneumoniae have spread to all regions of the world, often via resistant genetic clones. A
similar spread of resistance has been reported for othermajor respiratory tract pathogens,
including Haemophilus inﬂuenzae, Moraxella catarrhalis and Streptococcus pyogenes. To
develop and support resistance control strategies it is imperative to obtain accurate
data on the prevalence, geographic distribution and antibiotic susceptibility of respira-
tory tract pathogens and how this relates to antibiotic prescribing patterns. In recent
years, signiﬁcant progress has been made in developing longitudinal national and
international surveillance programs to monitor antibiotic resistance, such that the pre-
valence of resistance and underlying trends over time are nowwell documented for most
parts of Europe, and many parts of Asia and the Americas. However, resistance
surveillance data from parts of the developing world (regions of Central America, Africa,
Asia and Central/Eastern Europe) remain poor. The quantity and quality of surveillance
data is very heterogeneous; thus there is a clear need to standardize or validate the data
collection, analysis and interpretative criteria used across studies. If disseminated
effectively these data can be used to guide empiric antibiotic therapy, and to sup-
port—and monitor the impact of—interventions on antibiotic resistance.
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INTRODUCTION
Antimicrobial chemotherapy has been one of the
great areas of therapeutic success in clinical med-
icine, particularly in the second half of the 20th
century. Its use has resulted in dramatic reduc-
tions in both morbidity and mortality from infec-
tious disease and has made possible many
treatments that were previously either compli-
cated or limited by the risk of infection. However,
bacterial resistance to the effects of antibiotics is an
increasing problem that threatens the utility of
these therapies and compromises patient care.
This paper outlines the mechanisms of bacterial
resistance and the principles of microbiologic resis-
tance surveillance. It reviews the results of ongoing
surveillance programs assessing resistance in bac-
teria commonly implicated in community-acquired
respiratory tract infections (RTIs), and explores
the issues regarding how surveillance programs
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can best support strategies to control antibiotic
resistance.
Whilst some bacteria are known to be innately
resistant to speciﬁc classes of antibiotics, the major
health concern is the evolution and spread of
resistant strains derived from species that in the
past were fully susceptible. Mutations arising dur-
ing DNA replication and the acquisition of DNA
from other species, either as extrachromosomal
DNA (plasmids) or as chromosomal fragments,
give rise to new bacterial strains capable of resist-
ing the inhibitory activity of particular antibiotics.
These resistant strains have a selective advantage
over nonresistant strains during antibiotic expo-
sure, and may spread on a regional, national and
eventually global scale.
Resistance to antibiotics is widespread among
the bacteria commonly implicated in com-
munity-acquired RTIs (Table 1). For example,
in Streptococcus pneumoniae alterations in
penicillin-binding proteins (PBP), the targets for
penicillin and other b-lactam antibiotics, are pri-
marily responsible for resistance to these agents.
These alterations arise from hybrid PBP-encoding
genes, which have acquired DNA from other
Streptococcus spp. by the process of transformation.
Depending on which PBP is altered, strains with
different characteristics with regard to b-lactam
resistance (i.e. different ‘phenotypes’) are pro-
duced. Interestingly, Streptococcus pyogenes,
another Streptococcus spp. implicated in commu-
nity-acquired RTIs, has not become resistant to
penicillin and other b-lactam antibiotics, the rea-
sons for which are currently unclear [1,2].
With regard to macrolides, two main mechan-
isms are responsible for resistance in S. pneumo-
niae: target site modiﬁcation and efﬂux [3].
Macrolides target areas on the ribosomal RNA
in this organism. Modiﬁcation of the target site,
resulting from methylation of ribosomal RNA,
Table 1 Major mechanisms underlying antibiotic resistance in respiratory tract pathogens
Pathogen Clinical infection Antibiotics Major resistance mechanisms
Streptococcus pneumoniae Acute exacerbations of chronic
bronchitis; community-acquired
pneumonia; acute sinusitis; otitis
media
b-lactams Mosaicism in DNA-encoding
penicillin-binding proteins
Macrolides Modification (methylation) of
ribosomal RNA targets by erm
gene products. Efflux of 14- and
15-membered macrolides by mefA
gene products
Tetracyclines Protection of target by genes
encoding M protein
Chloramphenicol Inactivation by acetyl transferase
Co-trimoxazole Alterations in binding capacity
of dihydropteroate synthetase
and dihydrofolate reductase
Fluoroquinolones Mutations in genes encoding for
DNA topoisomerase IV (parC and
parE) and subsequently DNA
gyrase (gyrA). Hyperexpression of
endogenous multidrug efflux
system
Streptococcus pyogenes Pharyngitis Macrolides Modification (methylation) of ri-
bosomal RNA targets by erm
gene products. Efflux of 14- and
15-membered macrolides by mefA
gene products
Haemophilus influenzae Acute exacerbations of chronic
bronchitis; community-acquired
pneumonia; acute sinusitis;
otitis media
b-lactams b-lactamase production
Moraxella catarrhalis Acute exacerbations of chronic
bronchitis; community-acquired
pneumonia; acute sinusitis
b-lactams b-lactamase production
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confers resistance to the entire macrolide–lincosa-
mide–streptograminB (MLSB) family of antibiotics.
This form of resistance is mediated by products of
the erm genes and can be inducible (i.e. activated
on exposure to the antibiotic) or constitutive (i.e.
expressed at all times). Efﬂux-mediated resistance,
whereby the antibiotic is pumped out of the cell, is
conferred by themefAgenes. It results in resistance
to the 14- and 15-membered macrolides (e.g. ery-
thromycin, clarithromycin and azithromycin), but
not to the rest of the MLSB family. Both of these
types of macrolide resistance are also important in
S. pyogenes.
A further important feature of resistance in
S. pneumoniae is the widespread occurrence ofmul-
tiply resistant strains. Many penicillin-resistant
S. pneumoniae isolates are resistant not only to other
b-lactams, but also to non b-lactam antibiotics, in-
cluding erythromycin A and other macrolides,
tetracycline, chloramphenicol and cotrimoxa-
zole (trimethoprim-sulfamethoxazole) (Table 1).
A recent publication has documented 16 penicil-
lin-resistant and multidrug-resistant clones of
S. pneumoniae [4]. The most notable example of
these multidrug-resistant pneumococcal clones is
the serotype 23F clone (Spain23F-1), which was ﬁrst
identiﬁed in Spain in the early 1980s and is now
found in most regions of the world. Two recent
studies showed that between 22% and 39% of all
highly penicillin-resistant S. pneumoniae in the Uni-
ted States belong to this Spain23F-1 clone [5,6].
Furthermore, there are several serotype variants
of this clone that have been identiﬁed in various
countries across the world. Of particular concern
are recent reports of high-level resistance to ﬂuor-
oquinolones in S. pneumoniae isolates belonging to
international multidrug-resistant clones, includ-
ing the Spanish 23F clone (Table 1) [7,8].
b-lactamase production accounts for ampicillin
resistance in a notable proportion of Haemophilus
inﬂuenzae and is widespread in Moraxella catarrha-
lis. The b-lactamases act by cleaving the amide
bond of the b-lactam ring to produce an inactive
penicilloic acid derivative. They confer resistance
to penicillin and the aminopenicillins (e.g. ampi-
cillin and amoxycillin), and to some cephalos-
porins. The most common b-lactamases in H.
inﬂuenzae are TEM-1 and ROB-1, both of which
are inhibited by the b-lactamase inhibitor, clavu-
lanate. Generally, any one isolate of H. inﬂuenzae
produces only one of the two b-lactamases,
although rare isolates with both TEM-1 and
ROB-1 have been reported [9]. BRO-1 and BRO-
2 are the two b-lactamases found in M. catarrhalis;
it is thought that BRO-1 evolved from BRO-2 [10].
Promoter-up mutations increase ﬁtness of BRO-2,
explaining its present predominance. The random
distribution of BRO among M. catarrhalis ﬁnger-
print types indicates that BRO has spread by
horizontal transfer [10].
Although very rare at present, some strains of
H. inﬂuenzae do not produce b-lactamases, but are
still resistant to ampicillin (and other b-lactam anti-
biotics) and amoxycillin clavulanate. Resistance in
these b-lactamase-negative ampicillin-resistant
(BLNAR) strains of H. inﬂuenzae is mediated via
altered PBPs or diminished permeability.
The determination of the in vitro susceptibility
of bacteria to antibiotics has always been funda-
mental to the development and clinical usage of
these agents. Qualitative susceptibility testing
(usually using disk diffusion methods) is per-
formed routinely by laboratories across the world.
Much less frequently, often only during the pre-
clinical and early clinical development of a com-
pound, susceptibility is measured quantitatively
by determination of the minimum inhibitory
concentration (MIC). A particular strain of bacteria
is said to be ‘resistant’ to an antibiotic when the
MIC of that agent exceeds a predeﬁned ‘break-
point’ concentration. Breakpoint concentrations
are inﬂuenced by the potency of the antibiotic,
its pharmacologic/pharmacodynamic properties,
the site and type of infection, and the species of
bacterium. However, breakpoint concentrations
have been deﬁned by several different authorities
[e.g. the National Committee for Clinical Labora-
tory Standards (NCCLS), British Society for Anti-
microbial Chemotherapy (BSAC), etc.), which
complicates the interpretation of MIC values.
Susceptibility testing has become increasingly
important in recent years owing to the emergence
and spread of bacterial resistance. Local, national
and international antimicrobial resistance preva-
lence data are now of fundamental importance in
guiding empiric antimicrobial therapy (in indivi-
dual patients and on a policy/guideline level), in
researching the development of resistance, and in
supporting and monitoring strategies to combat
the spread of resistance. Surveillance is integral to
national guidelines for resistance control and its
optimization has been highlighted as a key area for
action by the European Commission [11], the
World Health Organization (WHO) [12] and the
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Interagency Task Force on Antimicrobial Resis-
tance in the United States [13].
Despite the unanimous opinion regarding the
importance of surveillance, there remainmany un-
certainties and obstacles hindering the implemen-
tation of optimal surveillance research [14–17].
PRINCIPLES OF SURVEILLANCE
Definition and aims
Public health surveillance is deﬁned by the Cen-
ters for Disease Control and Prevention (CDC) as
the ‘ongoing and systematic collection, analysis
and interpretation of health data essential to the
planning, implementation, and evaluation of pub-
lic health practice, closely integrated with timely
dissemination of these data to those who need to
know; the ﬁnal link of the surveillance chain being
the application of these data to the control and
prevention of human disease and injury’ [18].
Many aspects of this deﬁnition apply to microbio-
logic surveillance (Table 2). Therefore in the
following section, after considering the organiza-
tional aspects of surveillance, we will discuss the
criteria for good research in terms of the collec-
tion, analysis and interpretation of data as well
as issues regarding dissemination and applica-
tion of these data to support strategies to control
resistance.
Organization
Surveillance studies are funded from a variety
of sources and the major studies currently in pro-
gress have been reviewed recently [14,17,19]. In
Europe, national resistance surveillance is generally
undertaken by public health institutions and
ﬁnanced by public funds, although an increasing
numberof studies are sponsoredbypharmaceutical
companies. International surveillance, on the other
hand, has until recently been funded mainly by the
pharmaceutical industry [20–22]. Exceptions to this
include research conducted by the WHO.
The situation is somewhat different in the Uni-
ted States, where the CDC agency runs several
major antimicrobial surveillance programs for
both community- and hospital-acquired microor-
ganisms. The approach in the United States is
greatly facilitated by its governance by a single
political entity and by the use of standard suscept-
ibility testing procedures published by the NCCLS
[23,24]. The CDC also established the International
Nosocomial Surveillance Programme for Emer-
ging Antimicrobial Resistance (INSPEAR) in
1998, although this is hospital- rather than com-
munity-based [25].
The situation in Europe is changing as the Eur-
opean Union (EU) is now funding cross-border
studies that involve member states and geogra-
phically adjacent countries, thereby recognizing
the microbiologic irrelevance of national bound-
aries. For example, the EU-funded European Anti-
microbial Resistance Surveillance System (EARSS)
is a European network of national surveillance
systems that aims to aggregate comparable and
reliable antimicrobial resistance data for public
health purposes (http://www.earss.rivm.nl).
Industry-sponsored surveillance studies beneﬁt
from high levels of ﬁnancial funding. These pro-
grams are generally performed on a large scale and
involve many centers, centralized microbiologic
testing, and the inclusion of a wide range of anti-
biotics. For example, the Alexander Project [20,21]
and the PROTEKT study [26] are both speciﬁcally
focused on monitoring resistance in bacteria that
commonly cause community-acquired RTIs, while
the SENTRY Antimicrobial Surveillance Program
[22] collects a more diverse range of isolates.
More recently, another ﬁnancing approach to
the collection/production and dissemination of
antimicrobial resistance surveillance data has been
established [27]. Commercial organizations now
collect these data and sell them to customers. The
primary customers are pharmaceutical companies,
although some national public health institutions
are also making use of these services.
Although surveillance data are available from
an increasing number of countries (as reviewed
Table 2 Main functions of microbiologic surveillance
Quantification of resistance Resistance prevalence/
distribution
Changes over time
New/emerging forms
Guidance for antibiotic use: Individual patient level
Guidelines/policies
Research/education: Epidemiology of resistance
Link with antibiotic usage
Industry: Research and development
Licensing
Marketing/postmarketing
Resistance control: Design of strategies
Impact of strategies/
interventions
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below), data are still sparse from many areas,
including Central Europe, sub-Saharan Africa
and South-East Asia, where clinical microbiologic
facilities are often limited [28].
Study design
Surveillance of antimicrobial susceptibility can be
undertaken at many levels, ranging from small,
local hospital or laboratory studies to extensive
national or international data programs. Indivi-
dual studies may be organized as deﬁned time-
period point prevalence observations or by means
of long-term monitoring (i.e. ‘longitudinal’ stu-
dies). In some studies all isolates are sent to a
central laboratory for testing, while in others iso-
lates are tested by local laboratories and the results
are forwarded to a central database. Advances in
information technology now allow electronic
transmission of data and the WHONET program
has facilitated the standardization of test data
presentation [29].
Surveillance research can capture various types
of data. Most fundamentally, surveillance aims to
establish the prevalence of different forms of anti-
microbial resistance, the geographic distribution
of resistance, and the underlying trends over time.
Traditional methods of determining resistance are
phenotypic, i.e. they rely on the expression of
resistance by isolates. These methods are particu-
larly useful for detecting novel resistance pheno-
types. More recently, genotypic techniques, by
which resistance is detected by the analysis of
resistance-conferring genes, have been developed.
This technology is becoming more widely avail-
able, allowing epidemiologic research in many
more areas of the world where resistance rates
are high (e.g. Central/Eastern Europe). These
methods provide important information on the
mechanisms responsible for resistance and how
they are spreading and/or evolving. However,
genotypic research is relatively expensive and
time-consuming so, within public health pro-
grams, this type of analysis is usually limited to
speciﬁc studies of resistant isolates identiﬁed by
routine surveillance. Genotypic analysis is being
included as an integral part of some industry-
sponsored surveillance systems, e.g. SENTRY
and PROTEKT. In addition to antibiotic suscept-
ibility data, surveillance research can also collect
information on risk factors for acquisition, coloni-
zation, and/or for infection of resistant strains or
for high levels of resistance. Again, this type of
research is usually limited to studies where resis-
tance problems have been predeﬁned by conven-
tional surveillance [17].
Surveillance studies differ in terms of patient
selection, source of isolates, the range of pathogens
and antimicrobials tested, microbiologic metho-
dology and interpretative criteria. Any compari-
sons of resistance between studies demand
scrutiny of these variables to ensure comparison
of ‘like with like’. Unfortunately, details of such
criteria in surveillance reports are often not clearly
deﬁned. The most robust studies for comparative
analysis are likely to be those in which suscept-
ibility testing is performed either in one laboratory
using an internationally accepted standard proce-
dure, or in a number of laboratories applying the
same test procedures with external compliance
and quality control audit [30]. The use of a single,
central laboratory is generally considered to be the
best of these options. However, this approach
necessitates the transportation of isolates, which
is technically demanding and costly, as well as
requiring knowledge of appropriate transporta-
tion systems and familiarity with dangerous goods
transportation regulations and logistics.
Data collection
Ideally, research to measure the prevalence of
resistance among community-acquired RTI patho-
gens requires population-based studies of patients
presenting with these infections. In practice, such
research is expensive and logistically difﬁcult and
most surveillance studies rely on isolates sent by
community prescribers for microbiologic testing.
This may introduce bias into the data collection
because microbiologic testing has a limited role in
the treatment of community-acquired RTIs in out-
patients [31]. Initial antibiotic treatment for these
infections is usually prescribed empirically, i.e.
without knowledge of the causative pathogen or
its susceptibility proﬁle. Amicrobiologic diagnosis
is generally reserved for patients who are sicker or
who have failed to respond to initial antibiotic
treatment, in whom identiﬁcation of the causative
pathogen and its susceptibility proﬁle is clinically
important. Therefore, isolates analyzed in most
surveillance studies tend to be from these more
problematic patients. As the risk of resistance in
community-acquired RTI pathogens is linked with
previous antibiotic usage [32–35], analysis of these
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isolates may over-estimate the prevalence of resis-
tance in the general patient population. Never-
theless, the data do provide an early indication
of the development of resistance and its potential
dissemination through the general population.
Some surveillance programs, particularly in the
public sector, use routine sampling data. This
approach gives access to a very large data sample.
However, in addition to the bias described above,
such data suffer from the lack of a common deﬁni-
tion of patients and infections. The collection of
isolates from patients selected according to a
deﬁned protocol provides a more homogeneous
dataset.
Data collection must take account of a range of
factors that inﬂuence bacterial resistance patterns.
The site of acquisition of infection is of fundamen-
tal importance. Community- and nosocomially
acquired isolates of the same species can differ
markedly in their resistance proﬁles and must be
clearly differentiated. Demographic and clinical
characteristics are also relevant and wherever pos-
sible these details should be collected in parallel
with the clinical specimens. For example, the spec-
trum of pathogens isolated from children (parti-
cularly those attending day-care centers)—and the
resistance patterns therein—is different from that
observed in adults. Clearly, details of recent pre-
vious antibiotic usage are also important. Collec-
tion of patient data can be difﬁcult, however,
because surveillance research is normally con-
ducted by microbiology laboratories with limited
access to these data. The clinical source of isolates
provides another variable. Depending on the RTI
under diagnosis, isolates may be collected from
blood, bronchoalveolar lavage or middle ear ﬂuid,
sputum or nasopharyngeal material, sinus taps or
throat swabs. Some studies are restricted to one
particular source of isolates, while others analyze
isolates from several sources. Whatever their
source, recognition and removal of duplicate iso-
lates from individual patients is essential so that
resistance levels are not overestimated. However,
the deﬁnition of duplicates is not consistent among
studies [16]. Organisms causing infections should
also be differentiated from colonizing ﬂora.
Susceptibility testing
Several tests for determining antimicrobial sus-
ceptibility have been developed. One of the most
widely used methods is the agar disk diffusion
test. Although simple, economical and reproduci-
ble, this is essentially a qualitative method
whereby zones of inhibition are measured and
translated into predetermined categories as ‘sus-
ceptible’, ‘intermediate’ or ‘resistant’. Measuring
the inhibition of bacterial growth using broth or
agar dilution generates quantitative data (i.e.
MICs). The E test1 is a commercially available
method based on agar disk diffusion that provides
MICs by incorporating a predeﬁned antibiotic
gradient on a plastic strip, which is transferred,
accurately, to a surface-inoculated agar plate.
The results of these susceptibility tests are inﬂu-
enced by the test conditions used, e.g. inoculum
concentration, growth media and incubation con-
ditions. No test method is universally accepted as
the standard and differences between them can
result in apparent differences in antimicrobial
susceptibility [36]. The criteria established by the
NCCLS for use in the United States [23,24] are
widely used across theworld by individual labora-
tories and international industry-sponsored sur-
veillance programs [20–22,26]. However, even in
the United States compliance with these proce-
dures may be suboptimal [37]. In Europe, several
methods are in use and these undergo regular
review and revision [38–41]. The European Com-
mittee on Antibiotic Susceptibility Testing
(EUCAST) has been set up under the auspices of
the European Society of Clinical Microbiology and
Infectious Diseases to try to ensure that suscept-
ibility testing in Europe produces comparable
results and interpretations. EUCAST liaises with
NCCLS, the European Medicines Evaluation
Agency and with standards organizations and
has published several documents on methodology
and interpretation [42–44]. The European Study
Group on Antimicrobial Surveillance (ESGARS)
was also established to aid efforts to improve the
quality and standardization of susceptibility testing
across Europe, although its activities have been
limited to date. In France, theNational Observatory
for theEpidemiologyofBacterialResistance toAnti-
microbials (ONERBA: http://www.onerba.org)
has also published a valuable document on the
technical aspects of surveillance research.
Internal and external standardization of test
procedures is an important concern in multicenter
surveillance programs. The use of a central labora-
tory in which a standard approved procedure,
subjected to rigorous quality control, is used to
analyze all submitted isolates is advantageous in
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this respect. In contrast, local testing of isolates in
individual laboratories raises concerns over qual-
ity and comparability of the methods used,
although this level of standardization applies
more to qualitative than quantitative methodol-
ogy. However, most laboratories are involved in
national and international quality assurance pro-
grams and test-to-test variability has been greatly
improved by the standardization of basic para-
meters such as growthmedia, inoculum concentra-
tions and incubation conditions. Furthermore, in
routine laboratories, the introduction of instru-
mentation such as image analysis-based zone
readers and automated broth dilution systems
together with electronic data handling may help
to reduce assay variation and are labor-saving as
well [45]. Internationally, the WHO and the Inter-
national Society for Infectious Diseases conduct
training programs to improve standards of proﬁ-
ciency in microbiologic laboratories, particularly
in developing countries. Data from 189 labora-
tories in 39 countries participating in the WHO
External Quality Assurance System for Antimicro-
bial Susceptibility Testing suggest that there is
considerable scope for improving standards of
proﬁciency, particularly in the detection of peni-
cillin resistance in S. pneumoniae [46].
The choice of testing method used is dependent
on the time and resources available as well as the
rationale for performing the test. Qualitative data
are probably adequate for guiding the prescriber at
a local level and for monitoring changes in local
patterns of resistance. However, quantitative
determination of full end-point MICs is the most
useful in analytical terms, as this permits the
interpretation of laboratory data using existing
interpretative breakpoint MICs to deﬁne suscept-
ibility and resistance while allowing a ﬂexibility of
analysis where differences of opinion exist. This
method also permits retrospective re-analysis in
the light of changes in interpretative criteria. Most
importantly, determination of full end-point MICs
is essential if an assessment of the comparative
potency of antimicrobials and the relationship to
their pharmacokinetic behavior is to be made.
The frequency with which surveillance should
be undertaken is largely dictated by what is
required of the data. Continuous qualitative mon-
itoring is probably adequate as an aid to local
prescribing. In view of the ease of modern tra-
vel—which often occurs between areas with
greatly differing antimicrobial susceptibility
patterns—this approach requires continuedaware-
ness of the possibility of introduction and spread
of strains that differ from those of the local bacter-
ial ecology. Furthermore, not all alterations in
susceptibility occur as abrupt changes from ‘sus-
ceptible’ to ‘resistant’. Others occur over time, with
stepwise increases in MIC occurring until a pre-
viously treatable infecting organism becomes
refractory to therapy with a particular agent. For
example, in S. pneumoniae penicillin resistance is
generally manifested as incremental decreases in
susceptibility over time. In contrast, high-level
macrolide resistance in this species is acquired
abruptly in a single step. To anticipate these
changes, longitudinal research, providing detailed
knowledge of the quantitative susceptibility pat-
terns of strains in different countries over a period
of time, is essential. Where possible, isolates
should be retained for future re-analysis using
new analytical techniques and antimicrobials.
Interpretation
MIC breakpoints are selected on the basis of drug
pharmacokinetics, in vitro results with isolates of
known clinical responsiveness and nonrespon-
siveness, any known resistance mechanisms, and
overall distribution of MICs and zone diameters
with relevant clinical strains. Several sets of MIC
breakpoints are currently in use in different coun-
tries and are reviewed with variable regularity
[24,44,47,48]. Whilst the importance of standar-
dized criteria for breakpoints is well recognized,
the impact of resistance deﬁned on the basis of
MICs on clinical outcomes in patients with RTIs is
not clear (discussed by Metlay and Singer in this
supplement [49]). Infection-site-speciﬁc break-
points, based on the correlation of pharmacody-
namic/pharmacokinetic parameters with MICs
and clinical outcome data, may be more relevant
for guiding prescribing.
The optimal format for presenting surveillance
data has not been resolved. Full MIC distributions
are cumbersome but are the most comprehensive
and are invaluable as a reference source. MIC data
are frequently summarized as mode MICs, MIC50,
MIC90, and MIC ranges although condensing
information in this way is not ideal [50]. Resistance
rates are expressed most commonly as the propor-
tion of resistant isolates per total number of iso-
lates analyzed (prevalence). However, it is not
clear that the total number of isolates is the optimal
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denominator for public health purposes. Resis-
tance rates may also be expressed in the context
of patients (e.g. the number of patients with resis-
tant isolates/total number with positive cultures)
or hospital admissions (number of patients with
resistant isolates/number of admissions). Deno-
minators that are time-based (e.g. the number of
resistant isolates/number of days of hospitaliza-
tion or patient-days) may be more relevant to
clinicians [17].
Efforts to reassess the way surveillance data are
interpreted and presented should be oriented
toward their usefulness in supporting disease
management and efforts to control resistance.
Thus, in moving beyond the present focus on
conventional in vitro analyses, there is a need to
relate better the surveillance data to the clinical
impact of resistance [51].
Dissemination
Patterns of antimicrobial resistance are continually
evolving and it is important for the most up-to-
date information to be delivered promptly and in a
usable form to prescribers and workers involved
in resistance control. Publication by traditional
means can take several months and the amount
of detail that can be presented in standard journal
articles is necessarily limited. The inclusion of data
tables as supplementary appendices in electronic
versions of journal articles has been proposed
recently to address the latter issue [52]. Electronic
delivery of data is an excellent option as it allows
lengthy tables to be accessed. Accordingly, search-
able websites (with varying levels of data access)
have been set up for several studies, e.g. the
Alexander Project (http://www.alexander-net-
work.com), LIBRA (http://www.librainitiative.-
com), PROTEKT (http://www.protekt.org), and
ESGARS (http://www.earss.rivm.nl). These sites
are, or will be, regularly updated with the most
recently available data and some are linked to local
or national prescribing support systems. In addi-
tion, it should be noted that to promote resistance
control it is also important to disseminate surveil-
lance data and its implications to patients and the
general public using various media.
Application
Data from international surveillance studies can
aid in identifying resistance trends, help make
broad links with antimicrobial usage, and are
useful for educational purposes in drawing atten-
tion to what is a global problem. However, data
collected and used at the local level also play an
important role. Indeed, local surveillance studies
often provide more reliable regional prevalence
data than large international studies, which detect
resistance trends over a larger area. The balanced
solution is an integrated network of local and
international surveillance systems [53].
Although the collection of surveillance data
serves to deﬁne the problem of antimicrobial resis-
tance—and the need for continued and improved
surveillance is imperative—collection of data
alone will not serve to decrease resistance levels.
It is the interventions made in response to these
data that have the potential to contain the problem,
for example the optimization of antibiotic therapy,
the reduction of unnecessary prescribing, and the
use of better infection control measures. Routine
surveillance studies will play a crucial role in
demonstrating the impact of intervention pro-
grams. However, additional studies speciﬁcally
designed for this purpose and using other out-
comes may also be necessary [54,55].
SURVEILLANCE DATA
Western Europe
Several international surveillance surveys of bac-
terial resistance to antibiotics encompass Western
European countries. The Alexander Project and
the PROTEKT study are focused on community-
acquired RTI pathogens and include data from
Austria, Belgium, Eire, France, Germany, Greece,
Italy, The Netherlands, Portugal, Spain, Sweden,
Switzerland, and the UK (http://www.alexander-
network.com; http://www.protekt.org). Together
with national and local surveys from individual
countries, these ongoing studies provide substan-
tial information on antibiotic resistance patterns
for most parts of Western Europe.
Streptococcus pneumoniae
The most recent data from international studies
estimate the overall prevalence of penicillin-non-
susceptible S. pneumoniae (PNSP) across Western
Europe at 25–30% [PROTEKT (1322 isolates): inter-
mediate 8.7%, resistant 16.0%; Alexander (1149
isolates): intermediate 9.9%, resistant 19.6%]
(Figure 1) [21,56]. These data conﬁrm previous
ﬁndings. For example, 31% of isolates (n¼ 1537)
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8 (Suppl. 2), 12–42
Felmingham et al Surveillance of bacterial resistance 19
collected from Germany, Spain, France, Italy
and the UK in 1997–98 were penicillin nonsuscep-
tible [57]. The SENTRY antibacterial surveillance
system, which includes both nosocomial and
community-acquired isolates, reported high-level
penicillin resistance in 10.4% of European isolates
during the same period [22]. However, these over-
all ﬁndings mask considerable heterogeneity
within Western European countries. National pre-
valence rates of PNSP range from <5% in The
Netherlands to >50% in France (Figure 1).
Generally, pneumococcal penicillin resistance
occurs at a relatively low frequency in Northern
Europe. International studies have recently
reported a prevalence of PNSP of <15% in The
Netherlands, the UK and Sweden [21,56]. In con-
trast, penicillin nonsusceptibility is well estab-
lished in France and Spain, where its prevalence
exceeds 50%. Importantly, high-level resistance
predominates in these countries [21,56]. A Spanish
nationwide multicenter study of 1113 isolates col-
lected in 1996–97 found that 23.6%were penicillin-
intermediate while 36.5% were fully resistant. In
Ca´diz, 14.1% of isolates from 1995 were penicillin-
intermediate and 75.2% were fully resistant [58].
As mentioned previously, the Spanish 23F multi-
drug-resistant S. pneumoniae clone has now spread
from Europe to Asia, the Americas and South
Africa [59].
In the UK, levels of pneumococcal penicillin
resistance are rising in many regions, with high-
level penicillin resistance increasing from zero in
1988 to 3.3% in 1995 [60]. Longitudinal data from
the Alexander Project show a similar trend (0.1%
in 1992, 4.5% in 1996), while PROTEKT data from
2000 indicate an overall rate of PNSP in the UK of
14.3% (intermediate 8.8%; resistant 5.5%). How-
ever, in Northern Ireland and Eire, penicillin non-
susceptibility has reached 25%. Highly resistant
isolates are also emerging in Germany, with point
prevalences ranging from 0.3 to 3.9% [21,56,61].
Pneumococcal penicillin resistance remains
relatively uncommon in Scandinavia. In Finland,
no penicillin-resistant isolates were identiﬁed
among middle-ear isolates collected from children
in 1987–90, whereas 1.2% of 807 isolates collected
in 1995 were penicillin-resistant and 4.2% were
intermediate [62,63]. In Sweden, the prevalence of
penicillin resistance was 3–4% during 1994–97 and
only 1.3% in a population-based study conducted
in Stockholm in 1996 [64,65]. Higher prevalences
were reported in southern Sweden (increasing
from 3.1% in 1993 to 7.6% in 1995) but these had
stabilized by 1997, possibly as a result of preven-
tive measures implemented in the area [66]. A
multidrug-resistant clone (serotype 6B) intro-
duced into Iceland in 1989 made a major contribu-
tion to the emergence of pneumococcal resistance
in this country, which rose from close to zero in
1989 to 20% in 1993, and accounted for more than
70% of all penicillin-nonsusceptible isolates [67].
During the 1990s across Europe there was a
steady increase in macrolide resistance in both
penicillin-susceptible and -resistant S. pneumoniae
isolates. Both the Alexander Project and the PRO-
TEKT study reported an overall prevalence of
erythromycin resistance of 25% in 1999–2000
[21,56].
Macrolide resistance is most common in France,
Spain and Italy, where the respective prevalences
are 58%, 29–35%, and 32–43% [21,56,68,69]. The
rate of macrolide resistance exceeds 25% in Eire,
Figure 1 Prevalence of penicillin
nonsusceptibility in Streptococcus
pneumoniae across the world (var-
ious sources, data correct up to
February 2001).
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Greece and Belgium but is <10% in Finland, Ger-
many, the UK and Switzerland [21,56,63]. The
MLSB phenotype, which usually results in high-
level resistance (MIC 64mg/L), is the dominant
resistance phenotype in Europe [70,71].
In Spain, an analysis of antibiotic consumption
between 1979 and 1997 revealed a signiﬁcant
correlation between macrolide resistance and total
macrolide consumption, as well as between high-
level penicillin resistance and b-lactam consump-
tion, with use of long-acting macrolides and
cephalosporins contributing most to the effect
[72]. Inmost ofWestern Europe, levels of penicillin
resistance tend to correlate with levels of macro-
lide resistance. However, this pattern is not found
in Italy, where Alexander Project data suggest that
the national prevalence ofmacrolide resistance has
increased from <5% to >40% in the past decade
whilst penicillin resistance remains at around 10%
[73]. This relatively modest and stable level of
penicillin resistance may be explained by the
widespread use of parenteral cephalosporins in
Italy [74]. It may also reﬂect the broad range of
antibiotic classes used [69].
Haemophilus influenzae
Production of b-lactamase occurs in 11–19% of
Western European H. inﬂuenzae isolates. Again
there is considerable variation among countries,
with higher rates evident in the UK (15–18%), Eire
(17–26%), France (22–31%) and Belgium (16–18%)
and lower rates in Germany (3–7%), Italy (2–8%),
The Netherlands (3–6%) and Austria (3–4%)
[22,56,57,73]. In Finland, the proportion of b-lacta-
mase-positive isolates in childrenwith otitis media
increased from 8% to 24% from the 1980s to 1995
[63]. BLNAR H. inﬂuenzae strains remain rare
[56,73].
High level resistance to the macrolides is very
rarely observed. However, it should be noted that
the potency of macrolides against H. inﬂuenzae is
relatively poor—the mode MIC for erythromycin,
clarithromycin and azithromycin ranges between
1 and 8mg/L—and thus these agents are rarely
used to treat life-threateningH. inﬂuenzaeRTIs [75].
Moraxella catarrhalis
There has been a steady increase in the preval-
ence of b-lactamase-producing M. catarrhalis iso-
lates since the late 1980s, even in countries such
as The Netherlands where resistance among
other respiratory pathogens is relatively rare.
b-lactamase-producing isolates of M. catarrhalis
are currently widespread across Western Europe,
with very similar prevalences of >85% to 100%
being reported in most countries [56,57,73].
Streptococcus pyogenes
Penicillin resistance in clinical isolates of S. pyo-
genes remains unrecognized. With regard to
macrolide resistance, the UK was the ﬁrst country
to report resistance in S. pyogenes [76]. The levels of
erythromycin resistance amongst S. pyogenes from
Western Europe are very variable. Among 499
isolates collected from the region in the PROTEKT
study, erythromycin resistance was detected
most frequently in Italy (24.5%), Portugal (23.8%),
Spain (21.2%) and France (12.9%), but was not
found among isolates from Austria, Belgium, The
Netherlands, or the UK. Similarly, national studies
have highlighted high levels of macrolide resis-
tanceinItaly(30–40%)[69],Portugal(35.8%)[77]and
Spain (23.5% and 27%) [78,79]. Resistance was less
commonin isolates fromFrenchchildren (6.2%) [80]
and from outpatients in Sweden (<1%) [65].
The rise in erythromycin resistance in S. pyo-
genes in Finland during the late 1980s has been
particularly well documented. This was attributed
to a rise in macrolide usage—a subsequent reduc-
tion in macrolide consumption was followed by a
decrease in the prevalence of erythromycin resis-
tance [81,82]. Data from Spain (collected from 1986
to 1997) also support the hypothesis that wide-
spread use of macrolides, of which a large propor-
tion are those administered once or twice daily
(e.g. clarithromycin, roxithromycin, azithromycin
and dirithromycin), leads to an increased preva-
lence of erythromycin resistance in S. pyogenes [83].
Macrolide resistance phenotypes vary from
country to country. The ribosomal methylation
erm phenotype accounts for a substantial propor-
tion of resistant isolates in Italy and Portugal,
whereas the mefA efﬂux phenotype is dominant
in Spain [69,77–79]. In Italy, the erm methylation
macrolide-resistant phenotype has been correlated
with failure of macrolide treatment in children
with acute pharyngitis [84].
Conclusions
There is considerable heterogeneity in the preva-
lence of antibiotic resistance in community-
acquired RTI pathogens both among and within
countries in Western Europe. However, although
some adjacent countries may have very different
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levels of resistance (e.g. France and Germany, The
Netherlands and Belgium), there is a general trend
for resistance to be less common in countries in
Northern Europe compared with those in South-
ern Europe.
Resistance among pneumococci is increasing
and is now a major health concern even in coun-
tries where penicillin- and macrolide-resistant
S. pneumoniae were rare a decade ago. In Mediter-
ranean countries, such as France, Spain and Italy,
resistance among S. pneumoniae and/or S. pyogenes
isolates is already well established and alarmingly
high. b-lactamase-producing strains of H. inﬂuen-
zae are also increasingly prevalent in Western
Europe, while production of this enzyme is ubi-
quitous among M. catarrhalis isolates.
Patterns of antibiotic resistance in Western Eur-
ope are mirrored by community antibiotic sales,
which varymore than fourfold across the EU. Sales
are highest in France, Spain, Belgium and Portugal
and lowest in The Netherlands, Denmark, Sweden
and Germany [85]. The analysis of surveillance
data in conjunction with such information may
provide the basis for strategies to limit resistance at
a national and international level.
Central and Eastern Europe
Rates of antibiotic resistance in community-
acquired RTI pathogens vary considerably within
and between Central and Eastern European coun-
tries. Currently, few reports from this region have
been published in international peer-review jour-
nals, although the number of publications is grow-
ing. Much of the data presented in this section are
from national antibiotic reference centers, national
institutes of public health and different labora-
tories in Poland, Hungary, Romania, Bulgaria,
the Slovak Republic and the Czech Republic. Spe-
ciﬁcally, data have been obtained from the Alex-
ander Project [21,73,86], single publications, and
from personal communications. The following are
gratefully acknowledged for supplying data: Mar-
ianne Konkoly-Thege (Hungary), Paula Uraskova
(Czech Republic), Leon Langsadl, Jan Trupl,
Helena Hupkova and Krkoska Drusan (Slovakia),
Bojka Markova (Bulgaria), Dace Rukzite (Latvia),
Vasilica Ungureanu, Olga Dorobat and Irina
Codita (Romania), Arijana Boras (Croatia), Leonid
Strachounsky (Smolensk). Data from the PRO-
TEKT surveillance program [56] are also
discussed.
Streptococcus pneumoniae
Despite an overall increase in prevalence, the geo-
graphic differences between countries in Central
and Eastern Europe with respect to penicillin sus-
ceptibility in S. pneumoniae remain as they were
several years ago (Figure 1). Data collected in 1992
in Poland showed a relatively low prevalence of
PNSP of 6.6% (2% resistant/4.6% intermediate)
[87]; however, more recent data show an increase
in penicillin nonsusceptibility. The highest preva-
lence rates of PNSP strains in Central and Eastern
Europe have been reported from Hungary and
Romania (>40%), followed by Croatia (38%), the
Slovak Republic (>25%) and Poland (20%) [88].
The lowest prevalence rates have been found in the
Czech Republic (<5%).
Compounding the issue of increasing nonsus-
ceptibility is the fact that prevalence rates may
vary considerably within individual countries.
For example in Russia, 9% of isolates from inpa-
tients in Smolensk were reported to be penicillin
nonsusceptible (unpublished data) compared with
24% of those reported from Moscow [89]. Another
multicenter study in Russia, involving 305 naso-
pharyngeal isolates from healthy children attend-
ing day centers in Moscow, Smolensk and
Yartsevo, found an overall PNSP prevalence of
8% and a range of 3–13% between the centers
[90]. Published data from Estonia showed that
9% of S. pneumoniae nasopharyngeal isolates were
penicillin nonsusceptible [91]. Data indicate that
PNSP account for 20% of pneumococci isolated
from patients with community-acquired RTIs in
the Izmir area of Turkey and 36% of isolates
(n¼ 77) collected from Ankara, Turkey in the
PROTEKT studywere nonsusceptible [56]. Inmost
countries, the majority of PNSP strains show inter-
mediate penicillin susceptibility (as deﬁned by
an MIC of 0.12–1mg/L). However, in Poland
>50% of PNSP strains are fully resistant (i.e.
MIC 2mg/L) [21].
PNSP are often multiresistant, i.e. they are also
resistant to other antibiotics including macrolides,
tetracycline, cotrimoxazole and chloramphenicol.
The consumption of newmacrolides (i.e. clarithro-
mycin and azithromycin) has increased in recent
years in most Eastern and Central European coun-
tries. This trend has been associated with an
increase in macrolide resistance in some countries,
for example Hungary [56,92]. Conversely, a
decrease in the prevalence of macrolide resistance
has been noted in Poland and the Slovak Republic
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[21,86]. The reasons for this are unclear, particu-
larly in light of the high consumption of generic
macrolides in these countries.
Resistance rates to tetracycline in S. pneumoniae
range from 12% in the Czech Republic and 16% in
Hungary to 65% in Russia. The prevalence of
cotrimoxazole resistance is also increasing rapidly
and in many countries now exceeds 50%. These
trends reﬂect the very high usage of these anti-
biotics in Central and Eastern Europe, which is
mainly because of their low cost and local produc-
tion. Data from the Alexander Project (1996–97)
showed that the following proportions of fully
penicillin-resistant isolates of S. pneumoniae were
resistant to various agents: Slovak Republic (dox-
ycycline 30%, chloramphenicol 50%, cotrimoxazole
100%); Hungary (doxycycline 60%, chlorampheni-
col 53%, cotrimoxazole 100%); and Poland (dox-
ycycline 62%, chloramphenicol 39%, cotrimoxazole
77%) [21].
Haemophilus influenzae andMoraxella catarrhalis
b-lactamase-mediated ampicillin resistance in
H. inﬂuenzae is rare in Russia and Estonia (<1%
of isolates), but is increasingly prevalent in Poland,
and the Czech Republic (8% and 11%, respec-
tively). In comparison, this type of resistance is
more common in Romania (16%), Hungary (17%)
and, in particular, in the Slovak Republic (26%). In
the Central and Eastern European countries in-
volved in the Alexander Project (Czech Republic,
Slovak Republic and Poland) between 15% and
29% of isolates were resistant to cotrimoxazole,
whereas resistance to chloramphenicol and dox-
ycycline was 1% [73].
In most countries in this region, >90% ofM. cat-
arrhalis isolates produce b-lactamases. An excep-
tion is Hungary, where the prevalence of b-
lactamase production in M. catarrhalis has been
reported to be 61%.
Streptococcus pyogenes
Streptococcus pyogenes remains uniformly sensitive
to penicillin in Central and Eastern European
countries. Unpublished data suggest that resis-
tance of S. pyogenes strains to macrolides is not
found in Bulgaria and remains uncommon in
Slovakia and Romania (<10%). Somewhat higher
rates of macrolide resistance have been observed
in Russia (13%) and Poland (13%). While a similar
rate is observed among the overall population
in the Czech Republic (13%), more than 20% of
S. pyogenes strains recovered from older people
(>65 years of age) in this country are macrolide
resistant. Limited available data suggests that the
prevalence of macrolide resistance in S. pyogenes
may be as low as 2% in Turkey (n¼ 54 isolates) and
approximately 18% in Hungary (n¼ 28 isolates)
[56].
Antibiotic consumption
Antibiotic consumption data from Central and
Eastern Europe, expressed in deﬁned daily doses
(DDD)/1000 population/day (DID), show differ-
ences among Russia, Byelorussia, the Slovak
Republic, Poland and Hungary [93] (Figure 2).
Consumption of virtually all antibiotics is low in
Figure 2 Consumption of b-lactam (A) and macrolide (B)
antibiotics in Central and Eastern European countries
(various sources). Abbreviations: AMP¼ ampicillin;
AMX¼amoxicillin;AMX/CLAV¼amoxicillin–clavulanate;
AZI¼ azithromycin; CLA¼ clarithromycin; CLIN¼ clinda-
mycin; DDD¼defined daily doses; ERY¼ erythromycin;
LINC¼ lincomycin; PENG¼penicillinG (benzylpenicillin);
PEN V¼penicillin V (phenoxymethylpenicillin); SPIR¼
spiramycin.
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Russia and Byelorussia (<12DID) compared with
the Slovak Republic, Poland and Hungary
(>21DID). With regard to the macrolides and
lincosamides, there is a high (2.9–3.2DID) con-
sumption of these agents in Hungary, Poland
and the Slovak Republic. In contrast, in Byelorus-
sia, consumption of lincomycin is low (0.08DID)
and the use of clindamycin is virtually nonexistent
[90]. The same low usage has been observed for the
ﬂuoroquinolones in Russia, compared with high
usage of these agents in other countries. These
intercountry variations in antibiotic usage are
likely to be inﬂuenced by the pharmaceutical
companies operating in a particular area, the
availability of generic antibiotics and budget
considerations.
Optimal antibiotic usage in many Central and
Eastern European countries is hampered by a lack
of education among prescribers. Collaboration
between microbiology laboratories and clinicians
is generally poor. Indeed, the microbiology labora-
tory is not often viewed as an important aspect of
medicine and very few physicians specialize in
clinical microbiology. Many countries do not have
formal antibiotic policies [94] and most of the
knowledge about antibiotics among general prac-
titioners is gained from promotional materials
provided by pharmaceutical companies.
Conclusions
Very few resistance surveillance data from Central
and Eastern Europe are published in international
peer-review journals. The available data are lim-
ited to local studies and there is considerable
methodological variation. Importantly, in some
Eastern European countries, limited resources
do not allow the use of standardized quantitative
techniques of susceptibility testing (i.e. MIC mea-
surement). Consequently, it is difﬁcult to quantify
the problem regionally. Despite these limitations,
the available data indicate that:
 Rates of antibiotic resistance vary consider-
ably between countries in Central and Eastern
Europe.
 Resistance rates are higher for older antibiotics
(e.g. tetracycline, cotrimoxazole and chloram-
phenicol).
 Penicillin andmacrolide resistance appears to be
increasingly common in S. pneumoniae.
 Nonsusceptibility to penicillin is compounded
by cross-resistance to other antibiotics. For
example, cross-resistance between penicillin
and the macrolides may be particularly impor-
tant in countries such as Poland and the Slovak
Republic.
 Education on the rational usage of antibiotics,
particularly amongst general practitioners, is
clearly a high priority in this region.
North America
Antibiotic resistance in community-acquired RTI
pathogens in North America ﬁrst became evident
in the early 1980s with the emergence of b-lacta-
mase resistance in H. inﬂuenzae and M. catarrhalis
[95,96]. With the exception of the pneumococcal
surveillance program conducted by the United
States CDC, surveillance essentially consisted of
local point prevalence studies. At that time, non-
susceptibility rates were <5%, with essentially no
resistant strains being observed (MIC 2mg/L)
[97]. Indeed, the prevalence of PNSP was so low
that the CDC suspended surveillance between
1987 and 1992 [98].
However, the need for surveillance became evi-
dent in the early 1990s with the rapid emergence of
multidrug resistance in pneumococci and high
rates of resistance inH. inﬂuenzae andM. catarrhalis.
During the last decade, numerous national and
international hospital-based, community and hos-
pital-based, and community-based surveillance
systems have been established with the objective
of tracking antibiotic resistance in RTI pathogens.
Many of these programs have been in existence
for 2 or more years and can therefore provide
longitudinal data. These programs include: The
SENTRY Antimicrobial Surveillance Program
[99]; Focus Technologies (formerly MRL) [100];
CROSS (Canadian Respiratory Organism Surveil-
lance Study) [101]; ABC (Active Bacterial Core
Surveillance program of the CDC) [102]; the
Alexander Project [21]; the CBDN (Canadian Bac-
terial Surveillance Network) [103]; and PROTEKT
[56].
Streptococcus pneumoniae
Canada. In Canada, a strain of S. pneumoniae with
decreased susceptibility to penicillin was ﬁrst
reported by Dixon in 1977 [104]. However, PNSP
were recovered infrequently until the late 1980s.
Jette and Lamothe [105] performed susceptibility
testing on 468 strains collected between 1984 and
1986. No resistant strain was identiﬁed, and
only 1.3% showed intermediate susceptibility
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(MIC 0.12–1mg/L). In 1995, Simor et al. [106]
tested 1089 isolates of S. pneumoniae collected from
across Canada between 1994 and 1995 and found
8.4% to be of intermediate susceptibility and 3.3%
to be resistant.
Not only did the prevalence of PNSP rise during
the late 1990s, but resistance to other classes of
antibiotic also increased. From October 1997 to
November 1998, 1180 respiratory tract isolates of
S. pneumoniae were collected from 18 medical cen-
ters in nine of the 10 Canadian provinces [107].
Penicillin-intermediate and -resistant isolates
occurred with prevalences of 14.8 and 6.4%,
respectively. Rates of nonsusceptibility to cotri-
moxazole, tetracycline and macrolides were
12.2%, 10.6% and 9.3%, respectively. Of concern
was the observation by Chen et al. [103] that the
prevalence of ﬂuoroquinolone resistance among
pneumococci had increased in association with the
increased use of these agents. They found that the
prevalence of ciproﬂoxacin-resistant pneumococci
(MIC 4mg/L) increased from 0% in 1993 to 1.7%
in 1997–98 (P¼ 0.01). In adults, the prevalence
increased from 0% in 1993 to 3.7% in 1998. Of
even greater concern was their observation that
the degree of resistance signiﬁcantly increased
over the same time period. As a result of cross-
resistance, this threatens the activity of the new
respiratory ﬂuoroquinolones. Indeed, pneumococ-
cal resistance to the respiratory ﬂuoroquinolones
has recently been associated with clinical failures
[108].
There has been a signiﬁcant overall reduction in
the use of oral outpatient antibiotics, especially the
aminopenicillins, in Canada since 1995. This has
been associated with a stabilization in the preva-
lence of PNSP [109]. Current ﬁgures obtained from
a total of 2245 clinical isolates of S. pneumoniae
collected from 63 microbiology laboratories across
Canada during 2000 show a prevalence of 12.4%
and 5.8% for penicillin nonsusceptible and peni-
cillin-resistant isolates, respectively (Figure 1) [110].
Unfortunately, since 1993 the reduction in amino-
penicillin use has been offset by an increase in
macrolide use which, in turn, has been associated
with an increase in macrolide resistance. Macro-
lide resistance in S. pneumoniae has increased from
<3% in the early 1990s to 11% in 2000 [106,110].
United States. In 1978, Maki et al. [111] tested 243
isolates of pneumococci recovered from Madison,
Wisconsin. Only six strains had intermediate
susceptibility to penicillin and no strain was
found to be resistant. These low levels of resistance
continued to be seen throughout the 1980s. Nation-
wide studies by the CDC found rates of PNSP of
<5% and recovered only one isolate with high-
level resistance. However, this era of low-preva-
lence resistance in the United States came to an end
with the recognition in 1993 of antibiotic-resistant
pneumococci in the community in Kentucky and
Tennessee [112]. In Kentucky, 28% of pneumococci
cultured from middle-ear ﬂuid were penicillin
nonsusceptible. In Tennessee, 29% of pneumococci
isolated fromnasopharyngeal swabs from children
with otitis media enrolled at 17 sites in Memphis
were nonsusceptible. A total of 19% of the PNSP
were penicillin-resistant and 25%were multidrug-
resistant. By 1994–95, the proportion of PNSP
strains nationwide had increased to >23% [113].
Since then, numerous studies have documented
the increasing prevalence of PNSP and multidrug
resistance [21,22,102,114–116]. Doern et al. con-
ducted susceptibility testing on a total of 1531
recent clinical isolates of S. pneumoniae from 33
medical centers nationwide during the winter of
1999–2000. Of these isolates, 34.2% were penicillin
nonsusceptible and 21.5%were resistant (Figure 1).
MICs to all b-lactam antibiotics increased as peni-
cillin MICs increased. Rates of resistance to non b-
lactam agents were: macrolides 25.2–25.7%, clin-
damycin 8.9%, tetracycline 16.3%, chlorampheni-
col 8.3%, and cotrimoxazole 30.3%.
Haemophilus influenzae
Ampicillin resistance in H. inﬂuenzae was ﬁrst
documented in North America in 1975 and was
a result of the TEM-1 b-lactamase [117]. ROB-1 was
subsequently isolated in 1981 from an ampicillin-
resistant isolate of H. inﬂuenzae [118]. This subtype
of b-lactamase is considerably less prevalent than
TEM-1. BLNAR strains have recently been
reported in the United States [119], but still appear
to be relatively uncommon according to national
and multinational surveillance studies [120]. In
addition, resistance to orally administered cepha-
losporins, macrolides and other antibiotics (e.g.
chloramphenicol and tetracycline) has been
described, but no increase in their prevalence has
beennoted.Incontrast, thefrequencyofH. inﬂuenzae
isolates resistant to cotrimoxazole is increasing.
Canada. In Canada, the rate of b-lactamase produc-
tion in H. inﬂuenzaewas approximately 20% by the
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mid-1980s [121] and quickly rose from 24.0% to
31.3% during the 1990s [9,120,122,123]. Since 1995,
rates of b-lactamase production in H. inﬂuenzae
have actually decreased in association with a
reduction in aminopenicillin use in the outpatient
setting [124]. Rates of resistance to cotrimoxazole
were approximately 13% by the end of the 1990s
[123].
United States. b-lactamase-mediated resistance in
H. inﬂuenzae has become increasingly prevalent in
the United States. In 1983–84, the percentage of
b-lactamase-producing H. inﬂuenzae isolates was
15% [125]. In a subsequent surveillance study
performed in 1986, the overall rate of b-lactamase
production was 20% [126]. By 1994–95, 36% of
H. inﬂuenzae isolates produced a b-lactamase
[119]. Since 1996–97, no signiﬁcant change in these
ﬁgures has been noted; contemporary percentages
of b-lactamase-producing H. inﬂuenzae range from
33.4% in 1996–97 to 31.1% in 1997–98 [127,128]. The
prevalence of BLNAR has remained stable at <2%
[129]. The prevalence of cotrimoxazole resistance
has increased from almost zero in the 1980s to
>30% at present [129,130].
Moraxella catarrhalis
The ﬁrst b-lactamase-producing M. catarrhalis iso-
late was identiﬁed in North America in 1977 [131].
The dramatic rise in BRO b-lactamase-producing
M. catarrhalis strains observed in the last decade is
without precedent. The prevalence of BRO-produ-
cingM. catarrhalis is now almost universally >90%
[22,120,123,129]. AswithH. inﬂuenzae, resistance to
other classes of antibiotic, with the exception of
cotrimoxazole, was nonexistent. Co-trimoxazole
resistance is found in <8% of isolates in both
Canada and the United States [120,123,129].
Streptococcus pyogenes
Although resistance to penicillin has not been
reported in S. pyogenes, signiﬁcant levels of resis-
tance to some other antibiotics have developed in
certain geographic areas. This has been temporally
related to increased or excessive use of speciﬁc
antibiotics.
The best example is the development and
spread of macrolide resistance among S. pyogenes
in certain countries, which has been observed since
the 1960s [82]. Despite this, the prevalence of
macrolide resistance in Canada and the United
States remained <3% until recently [132,133].
However, macrolide resistance in S. pyogenes now
appears to be increasing in association with increa-
sing macrolide consumption [134,135]. Weiss et al.
[135] found rates of macrolide resistance of 4.6% in
the province of Quebec. In the San Francisco Bay
area of northern California, 32% of S. pyogenes
isolates from invasive disease were macrolide
resistant, compared with 9% of those from throat
cultures [136].
Conclusions
The number of surveillance programs established
in recent years has allowed us to not only track
the prevalence of antibiotic resistance in RTI
pathogens, but also to deﬁne the mechanisms
of resistance so that we might better understand
their epidemiology and the forces driving resis-
tance. The available data indicate that in North
America:
 Penicillin resistance in S. pneumoniae is increas-
ingly common and is associated with increasing
MIC levels and resistance to other agents, includ-
ing macrolides. The recent emergence of ﬂuor-
oquinolone resistance in this organism is also an
important concern.
 Up to a third ofH. inﬂuenzae isolates are resistant
to aminopenicillins and cotrimoxazole.
 Macrolide resistance in S. pyogenes is increasing.
As with macrolide resistance in S. pneumoniae,
this has occurred in association with increasing
macrolide consumption.
Latin America
Resistance to antibiotics in RTI pathogens appears
to be increasing in many countries in Latin Amer-
ica. Streptococcus pneumoniae, H. inﬂuenzae and
M. catarrhalis are the most common bacterial
pathogens isolated from community-acquired
lower RTIs. The prevalence of lower RTIs caused
by these pathogens is known to vary greatly
depending on geographic location and the same
is true for the rates of resistance to antibiotics
(Figure 1). Important differences exist between
the rates of resistance in different Latin American
countries and even between the rates in different
cities within each country.
S. pneumoniae
Approximately 6000 strains of S. pneumoniae have
been studied in Latin and South America since the
late 1980s (Table 3). All studies used NCCLS
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breakpoints, and almost all isolates were collected
from patients in the community. The prevalence of
penicillin nonsusceptibility ranged from 2.8% in
some countries to around 50% in others. In 1997,
the LASER study group surveyed 1100 S. pneumo-
niae isolates from seven Latin American and
Caribbean countries [137]. Of these, 23.5% were
nonsusceptible to penicillin (6.9% resistant/16.6%
intermediate) and a high prevalence of cross-resis-
tance to cotrimoxazole (44.6%) was observed. In
the same year, Odland et al. [138] analyzed 264
isolates from Latin American countries within the
SENTRY surveillance program. Among these,
9.9% were penicillin resistant and 45.8% were
penicillin intermediate. Sader et al. [139] also con-
ducted a similar study involving seven Latin
American countries during 1997–98. In this sur-
vey, of 553 S. pneumoniae isolates, 10.3% were fully
resistant to penicillin and 28.7% were intermedi-
ate. Similarly, in the Artemis project, which
included 643 S. pneumoniae isolates collected from
10 Latin American countries in 1997–98, penicillin
resistance was found in 8.2% of isolates and 10.3%
were intermediate [140].
During 1999/2000, 244 pneumococcal isolates
from ﬁve Latin American countries were analyzed
in the Global SMART (GSMART) surveillance
study [141]. Of these, 28% were nonsusceptible
to penicillin and 5% were fully resistant. Resis-
tance to cefotaxime was also observed in 10% of
isolates. Most recently, in the ongoing PROTEKT
program, 518 pneumococcal isolates from commu-
nity-acquired RTIs were provided by centers in
Brazil, Argentina andMexico in 2000 [56]. Overall,
42.1% of S. pneumoniae were nonsusceptible to
penicillin: 15.3% were resistant (MIC 2mg/mL)
and 26.8% were intermediate (MIC 0.12–1mg/L).
In addition, 15.3% of isolates were resistant to
erythromycin (MIC 1.0mg/L).
Brazil.Amulticenter survey conducted in 1995–96,
involving 10 Brazilian medical centers, found that
only 12.1% of 199 pneumococcal isolates were
nonsusceptible to penicillin [142]. In a slightly later
study conducted in 1997–98 by Focus Technolo-
gies, involving 361 S. pneumoniae isolates from ﬁve
Brazilian hospitals, 4.7% were resistant to penicil-
lin and 18.6% were intermediate [143]. Almost
100% of the isolates in both of these studies were
inhibited by newer ﬂuoroquinolones (sparﬂoxacin
and levoﬂoxacin). During the same period, Sader
et al. [144] analyzed 344 community-acquired RTI
isolates from Brazilian hospitals within the SEN-
TRY program. Among these, 2.3% of the 176 pneu-
mococcal isolates were penicillin resistant and
26.2% were intermediate. In the SIREVA-Vigı´a
program, conducted from 1993 to 1998, 2% of
S. pneumoniae isolates from Brazil were resistant
and 21.3% were intermediate [145].
In the Alexander Project, the prevalence of peni-
cillin nonsusceptibility in isolates (n¼ 76) collected
in 1997 reached 30.3% (1.3% resistant/28.9% inter-
mediate) [86]. Similarly, in the LSMART program,
3.1% of 130 pneumococcal isolates collected from
ﬁve Brazilian centers in 1999 were resistant to
penicillin and 23.8% were intermediate [146].
Among the resistant strains, 25% were also resis-
tant to cefotaxime. High levels of cross-resistance
Table 3 Susceptibility of Streptococcus pneumoniae in major recent surveillance studies performed in Latin America
Study Reference Location
No. of
strains Year S (%) I (%) R (%)
PROTEKT
(Latin America)
PROTEKT 2001 [56] Argentina,
Brazil and Mexico
518 2000 57.9 26.8 15.3
Azithromycin group Mendes et al. [148] Brazil 114 1999–2000 87.7 12.3 0
GSMART Sader et al. [141] Latin America 244 1999–2000 72.0 23.0 5.0
LSMART Mendes et al. [148] Brazil 130 1999–2000 73.1 23.8 3.1
SIREVA Hortal et al. [145] Latin America 1409 1994–99 65.7 19.7 14.6
Alexander Project Felmingham et al. [21] Brazil and Mexico 257 1998 54.1 28.0 17.9
SENTRY Sader et al. [144] Brazil 176 1997–98 71.6 26.1 2.3
SENTRY Sader et al. [139] Latin America 553 1997–98 61.0 28.7 10.3
Artemis Orrantia-Gradin et al. [140] Latin America 643 1997–98 81.5 10.3 8.2
MRL Critchley et al. [143] Brazil 361 1997–98 76.6 18.6 4.7
LASER Jacobs & Appelbaum [137] Latin America 1100 1997 76.4 16.6 7.0
SENTRY Odland et al. [138] Latin America 264 1997 44.3 45.8 9.9
S, susceptible; I, intermediate; R, resistant.
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to cotrimoxazole were also observed, but all
isolates were susceptible to levoﬂoxacin and gati-
ﬂoxacin.
Most recently, PROTEKT data from 2000 indi-
cate that 8.1% of 260 isolates from Brazil were fully
resistant, with a further 25.8% being intermediate
[56]. Only 6.5%were resistant to erythromycin, but
66.5% were nonsusceptible to cotrimoxazole.
Argentina. In an Argentinian surveillance program
conducted in 13 centers in 1995–96, 23% of pneu-
mococcal isolates recovered from blood were non-
susceptible to penicillin [147]. Similarly, in the
SIREVA-Vigı´a program, 20% of S. pneumoniae iso-
lates from Argentina during 1993–98 were fully
resistant to penicillin [145]. Data from the Artemis
project (1997–98), involving 10 Latin American
countries, showed that Argentina had the highest
rate of penicillin nonsusceptibility (27%), followed
by Mexico (21%), Venezuela (11%) and Brazil (3%)
[140]. According to PROTEKT data from 2000,
more isolates of S. pneumoniae (16.4%; n¼ 55) are
resistant to penicillin in Argentina than in Brazil,
although the number of isolates from Argentina is
small [56]. Patterns of resistance to other classes of
antibiotic are similar between the two countries.
Mexico. Most studies have shown Mexico to have
the highest prevalence of penicillin resistance
in S. pneumoniae among the countries of Latin
America. LASER study data from 1997 demon-
strated a higher rate of penicillin nonsusceptibility
in Mexico (40.8%) compared with Argentina
(19.1%) and Brazil (13%) [137]. Similarly, in the
SIREVA-Vigı´a program in Latin America (1993–
98), 20.8% of S. pneumoniae isolates from Mexico
were fully resistant to penicillin, and 28.6% were
intermediate[145].Thiscomparedwithcorrespond-
ing rates of 18.5% resistant/24.4% intermediate in
Uruguay and 20.0% resistant/15.5% intermediate
in Argentina. Sader et al. found an even higher
nonsusceptibility rate of 66.6% in isolates collected
during 1997–98 [139].
The latest published Alexander Project data
from 1998 indicate that 52.5% of 181 S. pneumoniae
isolates from Mexico were penicillin nonsuscepti-
ble (24.9% resistant/27.6% intermediate) [86].
More recently, the highest proportion of penicillin
nonsusceptible isolates in the PROTEKT Latin
American database was also observed in Mexico
(56.6%; n ¼ 203), of which 24.1% were resistant
and 32.5% were intermediate [56]. Resistance to
macrolides (27.6%) and tetracyclines (32.5%) was
also slightly more common in Mexico compared
with Brazil and Argentina.
Haemophilus influenzae
Fewer surveillance studies have been conducted
on H. inﬂuenzae than on S. pneumoniae in Latin
America. Overall, the rate of b-lactamase produc-
tion rarely exceeds 20% among the countries sur-
veyed.
In the Artemis project (1997–98), the percentage
of b-lactamase-producing strains ranged from 6%
in Colombia to 24% in Argentina [140]. Overall,
16% of the 605 isolates were b-lactamase positive.
In the SENTRY program conducted in the same
region during the same period [144], 12.7% of 361
H. inﬂuenzae isolates were found to be b-lactamase
producers. Among the participating countries,
rates of ampicillin resistance were highest in
Mexico (26%), followed by Argentina (17.1%),
Chile (12.5%) and Brazil (9.3%). A high level of
cross-resistance to cotrimoxazole (40%) was also
observed. Also during 1997–98, 9.4% of the 223
Brazilian isolates analyzed by Focus Technologies
were resistant to ampicillin and 2.2% were inter-
mediate [143]. Again, resistance to cotrimoxazole
(47.1%) was common in this study.
In a survey of 112 strains ofH. inﬂuenzae from 10
Brazilian medical centers in 1995–96, 12% were
found to be b-lactamase producers [142]. In the
Alexander Project, b-lactamase production was
detected in 10.3% of 126 Brazilian isolates collected
in 1996 [20]. Resistance to chloramphenicol was
relatively uncommon (11.9%) compared with
resistance to cotrimoxazole (29.1%). Similarly,
the Azithromycin Study Group found that 9.7%
of 247 Brazilian isolates ofH. inﬂuenzae collected in
1999–2000 were b-lactamase producers [148].
More recently, of the 520 isolates of H. inﬂuenzae
from Latin America analyzed in the PROTEKT
study, the prevalence of ampicillin resistance
(16.9%) was similar to levels in other major studies
[56]. The highest rate was found in Mexico (24.6%;
n¼ 195), followed by Argentina (19.2%; n¼ 52),
and Brazil (11.0%; n¼ 273). Among ampicillin-
resistant H. inﬂuenzae isolates, resistance to cotri-
moxazole varied from 30 to 70% in these countries.
Moraxella catarrhalis
The rate of b-lactamase production inM. catarrhalis
has been relatively constant, exceeding 90% in
most surveillance studies. Pan-Latin America data
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from the Alexander Project showed a steady
increase in the proportion of b-lactamase-positive
isolates from 75.7% in 1992 to 90.4% in 1996 [20].
Mendes et al. reported a similar prevalence of
89.4% in 1995–96 [142]. Since then, the rate of
b-lactamase production in this organism has been
documented at 91.8% in the Latin America SEN-
TRY study (1997–98) [144], 89% in the Artemis
project (1997–98) [140], and, in Brazil, at 100%
by the Azithromycin Study group [140,148]. PRO-
TEKT study data from 2000 support these ﬁnd-
ings, with b-lactamase production in Argentina,
Brazil and Mexico ranging from 97 to 100% [56].
Conclusions
The development and spread of resistance to
selected classes of antibiotics in community-
acquired RTI pathogens in Latin America is rising.
Several surveillance studies have been conducted
in the region and have yielded alarming results
and interesting variations.
The prevalence of infection caused by penicillin-
resistant pneumococci has increased dramatically
during the past two decades, particularly during
the last 5 years. Data from PROTEKT 2000 show a
penicillin nonsusceptibility rate of 42.1% among
pneumococcal isolates from the Latin American
countries surveyed (Argentina, Brazil andMexico).
It is also important to note that a particularly high
rate of penicillin nonsusceptibility (56.6%) was
detected among Mexican pneumococcal isolates,
with 24.1% fully resistant to penicillin.
Antibiotic resistance in S. pneumoniae is not con-
ﬁned to the b-lactams; many studies have docu-
mented the emergence of multiresistant strains of
pneumococci. In some countries, levels of macro-
lide resistance are currently as high or higher than
levels of penicillin resistance. While macrolide
consumption varies from country to country, those
countries with the highest consumption have the
highest overall prevalence of macrolide resistance.
By comparing penicillin resistance rates in
S. pneumoniae from several studies carried out
between 1992 and 2001 quoted in this paper, we
notice slight variations throughout the period. The
highest rate (55.7%) was reported by Odland and
colleagues in the SENTRY study carried-out in
1997 [138]. These variations are possibly because
of the origin of studied strains. As we know, the
rates of resistance may vary within the same
country and even between different cities within
the same country. In Latin American countries,
this is an important factor to consider because
these countries are characterized by very densely
populated urban areas and low-density popula-
tions in rural areas.
b-lactamase production by H. inﬂuenzae was
highest among isolates from Mexico (24.6% com-
pared with 19.2% and 10.9% in Argentina and
Brazil, respectively). For M. catarrhalis, in surveys
held in major Brazilian metropolitan areas with
populations of more than 3 million, the percentage
of b-lactamase-producing strains is greater than
95%.
Asia-Pacific
Rates of antibiotic resistance in community-
acquired RTI pathogens in some countries within
the Asia-Paciﬁc region are among the highest in
the world. However, wide variations exist across
this region.
Streptococcus pneumoniae
Resistance in S. pneumoniae is a particular con-
cern in Asia. From the PROTEKT Study, only
32% of respiratory S. pneumoniae isolates from
across Asia are fully susceptible to penicillin
[56]. Fifty-three percent exhibit high-level
resistance (MIC 2.0mg/L), while an addi-
tional 15% are of intermediate susceptibility
(MIC 0.12–1.0mg/L). Moreover, full macrolide
resistance (erythromycinMIC 1.0mg/L) iswide-
spread, occurring in 81% of S. pneumoniae isolates.
Behind these worrying ﬁgures lies considerable
variation in the prevalence of resistance (Figure 1).
Korea and Japan. The highest rates of penicillin and
macrolide resistance encountered in the PROTEKT
database are in South Korea. Here, 81% of S. pneu-
moniae isolates are penicillin nonsusceptible—70%
are fully resistant and 11% are intermediate (Fig-
ure 3) [56]. At least three-quarters of S. pneumoniae
isolates are also fully resistant to oral cephalospor-
ins such as cefuroxime, cefpodoxime and ceﬁxime.
Moreover, 86% are fully resistant to erythromycin
and the newer macrolides azithromycin and clar-
ithromycin.
These ﬁndings are in agreement with those of
the Asian Network for Surveillance of Resistant
Pathogens (ANSORP) Study, which surveyed
resistance rates in S. pneumoniae isolates collected
from 11 countries in Asia between 1996 and 1997
[149]. Korea again showed the highest prevalence
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of penicillin nonsusceptible isolates (79%: 55%
resistant/24% intermediate). Moreover, >60% of
penicillin-nonsusceptible isolates were resistant to
all other antibiotics tested, except vancomycin and
chloramphenicol.
Penicillin nonsusceptibility in S. pneumoniae is
also very common in Japan. The prevalence of
penicillin nonsusceptibility increased in Nagasaki
from 9% in 1988 to 37% in 1995 [150]. Ikemoto et al.
have also documented a steady rise in resistance in
S. pneumoniae in Japan over the last 20 years. Most
recently, this group reported that the rate of peni-
cillin nonsusceptibility had increased from 31% in
1997 to 46% in 1998 [151].
Current PROTEKT data show that 65% of
S. pneumoniae isolates in Japan are now nonsuscep-
tible (20% intermediate/45% resistant) (Figure 3).
Similar rates have also been reported by the
ANSORP study (38% intermediate/27% resistant)
[149] and the Alexander Project (23% intermedi-
ate/40% resistant) [86]. Macrolide and tetracycline
resistance are correspondingly common in Japan,
each being found in around 80% of isolates in
PROTEKT (Figure 3) [56] and other studies
[86,149].
South-East Asia. Relatively few surveillance data
are available for countries in South-East Asia
(Figure 1). The ANSORP Study revealed high
levels of penicillin resistance in S. pneumoniae in
Vietnam (intermediate 28%/resistant 32%) and
Thailand (36% intermediate/22% resistant) [149].
Rates were lower in Indonesia (intermediate 3%/
resistant 18%) and Malaysia (intermediate 6%/
resistant 3%). Singapore has shown rates of peni-
cillin nonsusceptibility, from 23% (intermediate
5%/resistant 18%) in ANSORP [149] to 53% (inter-
mediate 17%/resistant 36%) in the Alexander Pro-
ject [86]. Erythromycin and tetracycline resistance
is often more common than penicillin resistance in
this region.
China. Available data suggest that penicillin non-
susceptibility in S. pneumoniae is relatively infre-
quent (10–15%) in mainland China and is largely
intermediate in level [149,152]. Macrolide and tet-
racycline resistance is more common, however,
occurring in 30–50% of isolates, regardless of their
susceptibility to penicillin.
By contrast, Hong Kong is a major focus of
penicillin resistance. Current PROTEKT data show
that 57% of isolates are fully penicillin resistant
(Figure 3) [56]. Other national and international
studies have documented even higher rates of
nonsusceptibility [21,86,153]. For example, the
Alexander Project documented an increase from
59% in 1996 to 80% in 1999 [21,86]. Of particular
concern is the high prevalence of full resistance in
Hong Kong—74% in 1999 [21]—and the high
levels of resistance to broad-spectrum b-lactams
[56,86,153]. Penicillin resistance is also coupled
with high-level macrolide resistance, currently
found in approximately 75–80% of isolates (Figure
3) [21,56,153]. Moreover, 16% of PROTEKT isolates
from Hong Kong were reported as resistant to the
newer ﬂuoroquinolones, moxiﬂoxacin and levo-
ﬂoxacin, suggesting that clonal spread has
occurred.
Taiwan showed a rate of penicillin nonsuscept-
ibility of 38% (9% intermediate/29% resistant) in
the ANSORP study [149]. However, national stu-
dies have shown an increase from approximately
40% in 1995 to 54–56% in 1996–97 [154,155] and to
76% (25% resistant/51% intermediate) in 1998–99
[156]. Macrolide resistance is especially common
in Taiwan and is generally found in 60–95% of
S. pneumoniae isolates [149,154–156].
Indian subcontinent. Relatively low rates of penicil-
lin nonsusceptibility in S. pneumoniae have been
reported in India (4%) [149,157], Bangladesh
(13%) [158] and Pakistan (20%) [159]. In contrast,
41% of isolates from Sri Lanka were reported to be
Figure 3 Prevalence of nonsusceptibility to penicillin
(PEN), erythromycin (ERY) and tetracycline (TET) among
Streptococcus pneumoniae isolates from Asian countries
participating in PROTEKT [56].
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penicillin intermediate [149]. Cotrimoxazole resis-
tance is common in the Indian subcontinent and
has been reported in over 50% of isolates in India
and Bangladesh.
Middle East. The Middle East is emerging as an
area of increasing penicillin resistance. Over half of
S. pneumoniae isolates from Israel (resistant 36%/
intermediate 18%) [86], and Saudi Arabia (resis-
tant 18%/intermediate 44%) are nonsusceptible
[86], and >60% from Lebanon (13% resistant/
48% intermediate) [160] may be nonsusceptible.
However, macrolide resistance is less common at
present.
Australasia. Antibiotic resistance in S. pneumoniae
has increased rapidly in Australia. The percentage
of penicillin nonsusceptible isolates rose from 1%
in 1989 to 25% (17% intermediate/8% resistant) in
1999 [161]. Around 16% of isolates are now resis-
tant to erythromycin and tetracycline, while 45%
are resistant to cotrimoxazole [161].
Haemophilus influenzae
As in other parts of the world, b-lactamase pro-
duction byH. inﬂuenzae, conferring resistance to b-
lactams such as ampicillin and amoxicillin, is a
concern in Asia. However, like penicillin resis-
tance, the rates of b-lactamase production are
highly variable.
Latest PROTEKT data show that over 80% of
H. inﬂuenzae isolates from across Asia are suscep-
tible to ampicillin (MIC 1mg/L) [56]. However,
59% of H. inﬂuenzae isolates from South Korea
are fully ampicillin-resistant. Approximately one-
third of isolates are resistant to cotrimoxazole or
tetracycline.
Other studies have reported ampicillin resis-
tance in 55–58% of isolates of H. inﬂuenzae in Tai-
wan [154,156], 41% in Singapore [162], and 29% in
Hong Kong [21]. Rates of ampicillin resistance are
relatively low in Japan, at around 12–16% [56,163].
Recently, two new important trends have
emerged in ampicillin resistance in H. inﬂuenzae,
particularly in Japan. Firstly, some strains now
produce b-lactamases that are resistant to inhibi-
tion by the b-lactamase inhibitor clavulanate.
Hence, resistance to the widely used combination
of amoxicillin–clavulanate has been reported
[163]. Secondly, resistance has been reported in
BLNAR (ampicillin MIC 4mg/L) strains of
H. inﬂuenzae [163,164]. BLNAR strains have also
been shown to be resistant to newer cephalospor-
ins such as cefpodoxime and cefdinir [164]. Hae-
mophilus inﬂuenzae remains uniformly susceptible
to ﬂuoroquinolones and macrolides in Asia [56].
Moraxella catarrhalis
b-lactamase production is highly prevalent in
M. catarrhalis, with rates exceeding 90% in most
countries. However, M. catarrhalis generally
remains susceptible to the newer cephalosporins
and all isolates tested were also susceptible to
macrolides and ﬂuoroquinolones.
Streptococcus pyogenes
The PROTEKT study has not documented any
S. pyogenes isolates with resistance to penicillin
or ﬂuoroquinolones [56]. However, 18% of isolates
were resistant to erythromycin and the newer
macrolides. This prevalence is similar in Japan,
South Korea and Hong Kong. Approximately
30–40% of isolates are fully resistant to tetracycline.
Conclusions
Resistance to antibiotics is clearly increasing in
many Asian countries and is of particular concern
in S. pneumoniae. The patterns of antibiotic resis-
tance in Asia may be dependent on three factors:
 There is a high prevalence of certain resistant
serotypes of S. pneumoniae in some areas, e.g.
South Korea.
 The genetic relatedness between penicillin-resis-
tant S. pneumoniae strains from across Asia [149]
suggests that resistant clones have spreadwithin
and between countries.
 Genetic evidence also suggests that a nonsuscep-
tible clone related to isolates from Spain and
South Africa has been disseminated in Asia
[149,165].
Africa
Data concerning antibiotic resistance in commu-
nity-acquired RTI pathogens for most of Africa are
limited in comparison with those from Western
Europe and North America. In particular, no pan-
African studieshavebeenperformed toassess resis-
tance patterns across the continent and the region
has relatively little representation in international
studies. Currently only two African nations, South
Africa and Kenya, are involved in the Alexander
Project andonly one, SouthAfrica, in the PROTEKT
study (with effect from 2001/2002).
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Consequently, our present knowledge for much
of the continent is largely based on smaller local
studies prompted during the last decade by the
global concerns over resistance, particularly in
S. pneumoniae.
Streptococcus pneumoniae
The prevalence of penicillin resistance in S. pneu-
moniae varies between different African nations
(Figure 1).
North Africa. Despite its geographic proximity to
southern Europe, where penicillin-resistance rates
are amongst the highest in the world, Morocco
appears to have relatively low rates of resistance
[166]. Further eastwards across North Africa the
prevalence of penicillin resistance increases. The
percentage of nonsusceptible strains in Tunisia
was reported to have almost doubled to 14%
between 1994 and 1995 [167]. In Egypt, approxi-
mately 25% of isolates collected from childrenwith
pneumonia (n¼ 1635) between 1991 and 1993were
penicillin nonsusceptible [168]. A similar percen-
tage of isolates were resistant to cotrimoxazole.
West Africa. Recent data for resistance patterns in
West Africa are particularly scarce. Penicillin resis-
tance may be rare in Senegal and the Ivory Coast,
but may reach 20% in Nigeria [166]. In Ghana, 31%
of S. pneumoniae clinical isolates collected between
1994 and 1996 were resistant to penicillin [169].
Resistance to erythromycin and cotrimoxazolewas
less common and all isolates were susceptible to
ceftriaxone. A pediatric study in a rural region of
the Gambia showed a low prevalence (<10%) of
resistance to penicillin, cotrimoxazole and chlor-
amphenicol, suggesting that pneumococcal anti-
biotic resistance is not a major problem in this area
[170].
East Africa. With regard to East Africa, evidence
from the early 1990s suggested that pneumococcal
penicillin resistance is rare or even absent in Ethio-
pia [171]. However, a more recent hospital-based
study of pyogenic meningitis-causing bacteria
from 1993 to 1995 has reported a 17% prevalence
of S. pneumoniae with intermediate penicillin sus-
ceptibility [172]. In the same study a 13% suscept-
ibility to cotrimoxazole (0% resistant/13%
intermediate) and chloramphenicol (11% resis-
tant/2% intermediate) was also reported. By con-
trast, penicillin resistance appears to be an
increasing problem in Kenya. Data published in
1996 indicate that 25% of sputum and blood iso-
lates collected from outpatients in Nairobi with
pneumonia, most of whom were human immuno-
deﬁciency virus (HIV) positive, were penicillin
nonsusceptible [173]. Reduced penicillin suscept-
ibility was signiﬁcantly more common in sputum
isolates (35%) than blood isolates (18%; P¼ 0.013).
More recently, the Alexander Project has indi-
cated that penicillin nonsusceptibility is increas-
ingly prevalent in Kenya. Almost half of isolates
collected in 1999 were penicillin nonsusceptible
[21]. However, resistance was largely intermediate
(47% of isolates), with full resistance uncommon
(1.4%). Although penicillin-intermediate and
-resistant isolates are often also resistant to macro-
lides, this has so far not been shown to be the case
in Kenya, and macrolide resistance remains rare.
Central Africa. Resistance patterns in nasopharyn-
geal isolates collected from ill pediatric outpatients
(n¼ 371) in the Central African Republic were
recently reported [174]. This survey, conducted
in 1995 as part of a governmental and WHO acute
respiratory infection program, suggested that
resistance in S. pneumoniae is not yet a major con-
cern in this region. Intermediate penicillin resis-
tance was found in 9% of S. pneumoniae isolates
and none were fully resistant. The rate of resis-
tance to cotrimoxazole (7%) was comparable,
while tetracycline resistance was far more preva-
lent (42%).
Further south, 21% of S. pneumoniae clinical iso-
lates collected from Rwanda between 1984 and
1990 were penicillin intermediate, but tetracycline
resistance was common [175]. In Zambia, high-
level tetracycline resistance was found in 23% of
nasopharyngeal isolates from children (n¼ 126),
while 14% were penicillin intermediate [176].
Overall, a third of nasopharyngeal isolates in the
latter study showed some resistance to at least one
type of antibiotic. Likewise, in Botswana, approxi-
mately half of nasopharyngeal isolates from chil-
dren (n¼ 249) were resistant to at least one
antibiotic although only 7% showed multiresis-
tance to three or more agents [177]. Almost a
quarter of isolates were penicillin nonsusceptible.
Finally, a small study in Zimbabwe showed that
7% of S. pneumoniae isolates were penicillin non-
susceptible [178]. Notably, these isolates mostly
showed full penicillin resistance and were also
resistant to erythromycin.
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South Africa. The primary site of pneumococcal
penicillin resistance in Africa, and the country in
which most research has been performed, is South
Africa. Indeed, the ﬁrst global reports of multi-
resistant S. pneumoniae came from South Africa in
the late 1970s.
Since then, the prevalence of resistance in
S. pneumoniae in South Africa has increased alar-
mingly. Between 1979 and 1986, the prevalence of
resistance to one or more agents in pneumococcal
blood isolates increased from 4% to 14% [179]. By
1992, 40% of isolates (n¼ 207) causing community-
acquired meningitis or bloodstream infections in
South African children were penicillin-intermedi-
ate (38.6%) or -resistant (1.4%) [180]. Four percent
of isolates were multiresistant to three or more
agents tested.
The Alexander Project has shown that the pre-
valence of penicillin resistance in South Africa has
continued to rise (Figure 4) [21,86]. Centres in
Johannesburg have participated in the Alexander
Project since 1996. Of the isolates collected in 1999,
79%were penicillin nonsusceptible [86], indicating
that South Africa remains a global focus of peni-
cillin nonsusceptibility in S. pneumoniae. However,
penicillin resistance in South Africa remains
mainly intermediate in level; full resistance is far
less prevalent here than in Hong Kong or southern
Europe.
Almost a quarter of S. pneumoniae isolates from
South Africa now show full erythromycin resis-
tance, with 40–50% of penicillin nonsusceptible
isolates showing cross-resistance to macrolides.
Over 90% of erythromycin-resistant isolates are
also resistant to clindamycin. In terms of genetic
phenotypes, a study from South Africa carried out
in 1999 showed that 57% of erythromycin-resistant
S. pneumoniae expressed erm genes and 13%
expressed mef genes [165]. Moreover, 31% of the
erythromycin-resistant S. pneumoniae expressed
both erm and mef genes and were highly resistant
to erythromycin and clindamycin. Most (83%) of
these strains belonged to a single multiresistant
serotype 19F clone. Fifteen to 20% of isolates from
1996 to 1997 tested in the Alexander Project were
resistant to doxycycline or cotrimoxazole [86].
Interest in pneumococcal infection in Africa has
increased in recent years not only because of the
spread of antibiotic resistance, but also because of
its association with HIV infection [181]. HIV is a
major health-care problem inmany areas of Africa,
including South Africa. HIV-infected adults and
children are at increased risk of S. pneumoniae
infection and the causative strains are more likely
to be penicillin resistant than those causing infec-
tions in non-HIV-infected patients [182–184]. Vac-
cination against pneumococcal infection may
reduce its impact in HIV-positive patients, but
further research is required to establish the efﬁcacy
of this approach.
Other pathogens
There are few data concerning resistance rates in
othercommunity-acquiredRTIpathogens inAfrica.
Evidence suggests that ampicillin resistance is
uncommon (10%) in H. inﬂuenzae in Egypt
[168], Ethiopia [171,172], Nigeria [185–187], Gam-
bia [188], and the Central African Republic [174].
Similarly, resistance rates of H. inﬂuenzae to cotri-
moxazole and chloramphenicol in Ethiopia are
also low (6% and 3%, respectively) [172]. Around
30% ofM. catarrhalis respiratory isolates in Nigeria
were resistant to ampicillin in one study [187].
Further south, ampicillin resistance was present
in around a quarter of nasopharyngeal H. inﬂuen-
zae isolates in Botswana [177]. In South Africa 11–
14% of H. inﬂuenzae isolates are ampicillin resis-
tant, largely on account of b-lactamase production
[189,190]. Resistance to cotrimoxazole is found in
10–20% of isolates, while erythromycin resistance
is widespread, occurring in around 85% of isolates
[189,190]. A third study from South Africa has
reported a similar low prevalence of resistance of
H. inﬂuenzae to a wide range of antibiotics, includ-
ing ampicillin (8%), cotrimoxazole (10%), tetracy-
cline (12%) and chloramphenicol (8%), while
resistance to erythromycin was reported at 43%
[191]. However, 22% of isolates collected in this
study were resistant to three or more agents.
Figure 4 Changes in penicillin and macrolide-resistance
prevalence in respiratory Streptococcus pneumoniae isolates
in South Africa [21,86].
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Antibiotic usage and resistance
There can be little doubt that the spread of anti-
biotic resistance in S. pneumoniae is due, at least in
part, to the use of antibiotics. A study conducted in
the southern African nation of Lesotho showed
that children in the capital city of Maseru (n¼ 196)
were signiﬁcantly more likely than rural children
(n¼ 324) to carry penicillin- or tetracycline-resis-
tant pneumococcal nasopharyngeal isolates [192].
In association with this ﬁnding, city-dwelling chil-
dren tended to visit clinics at an earlier age, had
greater antibiotic exposure, were more frequently
hospitalized and attended day-care centers more
often than their rural counterparts.
Of 160 mothers from Zambia questioned in a
survey, 62% knew that antibiotics killed germs or
treated infections [176]. Almost half were dissa-
tisﬁed when antibiotics were not given for their
sick children and 75% said that antibiotics were
available outside the medical-care system. Almost
all the mothers (93%) normally completed anti-
biotic courses, although 62% admitted to keeping
leftover antibiotics for future use.
Conclusions
Data concerning resistance patterns in Africa, and
the factors driving resistance, are scarce. Unfortu-
nately, the socioeconomic conditions in some
countries may create barriers to correct antibiotic
usage and to research.
South Africa remains a global focus of increas-
ing resistance in S. pneumoniae. This trend is of par-
ticular importanceforthetreatmentofmeningitis,as
resistance is clearly associated with failure of peni-
cillin treatment. At present, its impact on the treat-
ment of community-acquired RTIs is less certain
because the levels of largely intermediate resistance
may be less likely to affect clinical outcome in these
infections. Nonetheless, the potential for increased
rates of high-level penicillin and macrolide resis-
tance gives reason for considerable concern.
OVERALL CONCLUSIONS
Considerable progress has been made in develop-
ing national and international research pro-
grams to monitor resistance to antimicrobials.
The prevalence of resistance to antibiotics among
community-acquired RTI pathogens is now well
documented in most of Europe, parts of Asia and
theAmericas,andisalarminglyhigh insomeplaces.
Despite the expansion of international studies, the
quantity and quality of resistance surveillance data
from many areas, especially developing regions of
Central America, Africa, Asia and Central/Eastern
Europe, remainpoor.Mortality fromRTIs is highest
in these regionsand limited therapeutic optionsand
poorly regulated prescribing practices are likely to
fuel the spread of resistance.
Furthermore, there are still considerable chal-
lenges to the provision of reliable surveillance
data, in relating these data to antibiotic-prescrib-
ing patterns, and in the application of this infor-
mation to support resistance control strategies.
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